Malaria: Symptoms, Transmission, Prophylaxis, and Vaccine

What is Malaria?

Malaria is a serious, potentially life-threatening infectious disease caused by a parasite and transmitted primarily through the bite of infected mosquitoes. It is most prevalent in tropical and subtropical regions, though very rare, sporadic cases can occasionally occur in temperate climates.

Malaria, though virtually eliminated from Western countries, remains one of the leading causes of death worldwide. This is especially true among children in sub-Saharan Africa. Travelers to endemic regions face a real and concrete risk of infection, making pre-travel prevention essential.

Several forms of the infection exist, caused by different species of the Plasmodium parasite. The most dangerous form is caused by P. falciparum, predominantly found in sub-Saharan Africa.

Common Symptoms

Typical malaria symptoms include:

• Chills and rigors
• Flu-like symptoms
• High fever
• Nausea and vomiting
• Diarrhoea
• Jaundice (yellowing of the skin and eyes)

Diagnosis is confirmed through blood tests. While malaria can be fatal if untreated, effective and specific treatments are available for all forms. The best strategy, however, remains prevention.

---

Transmission and Contagion

Malaria is caused by protozoan parasites of the genus Plasmodium. Five species are capable of infecting humans:

P. falciparum is by far the most feared species, capable of causing rapidly severe, potentially fatal infections if not promptly treated.

The Transmission Cycle

Malaria is transmitted through the bite of an infected female Anopheles mosquito:

1. A mosquito bites an infected person and ingests blood containing the malaria parasites
2. The parasites develop and multiply inside the mosquito over approximately 7–14 days
3. During the mosquito’s next blood meal, the mature infective forms (sporozoites) are injected into the new human host through the mosquito’s saliva
4. In the human body, sporozoites travel to the liver, where they multiply rapidly
5. After several days, thousands of merozoites are released from the liver into the bloodstream, where they invade and destroy red blood cells
6. Some parasites stay in the liver, where they keep multiplying in cycles. Every few days, they release more parasites into the blood.

This cyclical destruction of red blood cells is what drives the characteristic fever pattern of malaria.

Does Malaria Spread Person to Person?

Malaria cannot be transmitted directly between people. This includes sexual contact, casual contact like handshaking or hugging, or respiratory secretions.

However, because the parasite lives inside red blood cells of an infected person, transmission can exceptionally occur through:

• Blood transfusions
• Organ transplantation
• Shared needles or syringes contaminated with infected blood (relevant in drug use contexts)
• Mother to child (vertical transmission): before or during childbirth, causing congenital malaria in the newborn

The Malaria Mosquito

The infective form of the parasite (sporozoite) is housed in the salivary glands of female Anopheles mosquitoes, from which it is injected into the human host during feeding.

Key characteristics of Anopheles mosquitoes:

• Female mosquitoes require blood meals to nourish their eggs
• Eggs are deposited in water, such as puddles, hoof prints, plant saucers, rice paddies, or irrigation channels. There, larvae hatch and mature into adults. This explains why malaria transmission is higher in rainy seasons and in areas with stagnant water.
• The mosquito is primarily active at night, specifically between dusk and dawn. This makes these hours the highest-risk period for bites, so it’s the most important time for protective measures.

Risk Factors

Anyone can be infected with malaria if exposed to infected mosquitoes. The majority of cases occur in residents of endemic countries. In non-endemic countries, the risk arises primarily from travel to malaria-endemic regions (tropical Africa, parts of Asia, Central and South America, and the Pacific).

People at heightened risk of severe disease include:

• Young children (especially under 5 years)
• Pregnant women
• Immunocompromised individuals
• People without prior immunity (travelers from non-endemic regions)

---

Incubation: When Do Symptoms Appear?

The time from infection (mosquito bite) to the onset of symptoms is known as the incubation period and varies by parasite species:

Important: For P. vivax and P. ovale, parasites can remain dormant in the liver (as hypnozoites) for months to years. They may reactivate later, causing clinical disease. In some cases, this can occur up to 4 years after the initial infection. This is why malaria must be considered even in individuals who traveled to endemic areas long before becoming ill.

---

Symptoms

Symptom severity varies depending on the Plasmodium species involved. Initially, the patient may appear irritable and fatigued, with poor appetite and disturbed sleep.

The Classic Fever Cycle

The characteristic malaria pattern consists of recurring cycles of:

1. Sudden chills and rigors lasting 1–2 hours, during which fever rises rapidly.
2. High fever, often exceeding 40°C and persisting for 2–7 hours, may occur; paradoxically, many patients report feeling relatively well despite the elevated temperature.
3. Profuse sweating as body temperature falls

This cycle recurs at characteristic intervals:

• Every 48 hours for P. vivax and P. ovale (“tertian” malaria).
• Every 72 hours for P. malariae (“quartan” malaria).
• No defined periodicity for P. falciparum – fever may be high and recur every 36 to 48 hours, or it may present as a persistent, lower-grade continuous fever.

Fever is the cardinal symptom of malaria.

Without treatment, non-severe forms may seem to resolve on their own. However, they can recur as intermittent febrile episodes, which in P. vivax infections may last up to 3–4 months. falciparum* infections.

Additional Symptoms

Beyond fever, malaria can cause:

• Headache
• Nausea and vomiting
• Diarrhoea
• Muscle aches (particularly back pain and abdominal pain)
• Enlarged spleen (splenomegaly)
• Enlarged liver (hepatomegaly)
• Tachycardia and delirium from high fever
• Cerebral involvement: seizures, loss of consciousness
• Renal involvement: abnormally reduced urine output (“blackwater fever”, dark urine caused by haemoglobin release)

---

Risks and Complications

With appropriate antimalarial drugs, malaria is typically curable within two weeks with an excellent prognosis. Without treatment, however, it can be fatal, especially in young children who are already weakened by malnutrition. These children face a high risk of permanent complications, including:

• Chronic recurrent infections
• Neurological and cognitive deficits
• Behavioural disorders
• Epilepsy

Severe anaemia is one of the most common life-threatening complications, caused by the parasite’s mass destruction of red blood cells. Anaemia reduces the blood’s capacity to carry oxygen to organs and muscles, causing profound weakness, drowsiness, and collapse.

Other serious complications of severe malaria include:

• Hepatic failure and jaundice
• Shock (sudden severe drop in blood pressure)
• Pulmonary oedema (fluid accumulation in the lungs)
• Acute Respiratory Distress Syndrome (ARDS)
• Hypoglycaemia (critically low blood glucose)
• Renal failure
• Splenic enlargement or rupture
• Severe dehydration

Malaria and Pregnancy

Malaria during pregnancy is particularly dangerous and increases the risk of:

• Maternal and fetal anaemia
• Fetal death
• Spontaneous abortion (miscarriage)
• Low birth weight
• Neonatal and infant death

Pregnant women traveling to malaria-endemic regions should receive specific pre-travel medical counseling and appropriate prophylaxis.

---

Diagnosis

When malaria is suspected, especially after travel to an endemic area, speed of diagnosis is critical. Clinical signs alone (such as fever) are insufficient, as they overlap substantially with other tropical and viral illnesses. Modern diagnostic protocols involve multiple levels of investigation.

Microscopic Examination (Gold Standard)

Direct microscopic examination of blood remains the international reference standard. Two types of blood film preparations are made from a peripheral blood sample:

• Thick blood smear: Examines a larger blood volume, making it easier to detect the parasite even at low levels (high sensitivity).
• Thin blood smear: Allows precise identification of the Plasmodium species and quantification of the parasitaemia, which is the percentage of infected red blood cells. This serves as a key indicator of disease severity.

Rapid Diagnostic Tests (RDT)

Immunochromatographic tests detect specific parasite antigens in the blood. Extremely practical for immediate diagnosis, especially in emergency settings or where expert microscopists are unavailable, RDTs can provide results in under 20 minutes. They generally distinguish between P. falciparum* and other species.

Molecular Diagnostics (PCR)

Polymerase Chain Reaction (PCR) is the most sensitive diagnostic technique available. It is used to:

• Confirm species identification in doubtful cases.
• Detect mixed infections (simultaneous infection with multiple species).
• Identify very low parasitaemia undetectable by microscopy.
• Detect genetic mutations associated with drug resistance, which is essential for treatment planning in regions where resistance is prevalent.

Supportive Investigations

Beyond parasite detection, the following tests evaluate the systemic impact of malaria:

• Complete blood count (CBC): Assesses degree of anaemia and platelet count (thrombocytopenia is common).
• Renal and hepatic function tests.
• Blood glucose: To exclude hypoglycaemia (particularly dangerous in children and pregnant women).
• Urinalysis: Checks for haemoglobin in urine, which is a sign of massive haemolysis.

---

Treatment

The primary goal of malaria treatment is the rapid and complete elimination of parasites from the blood to prevent progression to severe disease and death. Treatment must be prompt and targeted, selected based on:

• The Plasmodium species involved
• Clinical severity
• The probable drug sensitivity profile (based on the geographic area where infection was acquired)

Artemisinin-Based Combination Therapies (ACT)

For uncomplicated P. falciparum malaria, international guidelines (WHO) recommend ACT regimens as first-line treatment. These combine an artemisinin derivative, which rapidly reduces parasite burden, with a long-acting partner drug that clears residual parasites.

• Artemether + lumefantrine (most widely used globally)
• Dihydroartemisinin + piperaquine
• Artesunate + amodiaquine

Treatment of P. vivax and P. ovale Infections

These species require two-component treatment:

1. Standard antimalarials (e.g., chloroquine or ACT, depending on local resistance patterns) to treat the blood-stage infection
2. Primaquine or tafenoquine to eliminate dormant liver forms (hypnozoites) and prevent relapses months or years later

Critical safety check: Before prescribing primaquine or tafenoquine, a G6PD (glucose-6-phosphate dehydrogenase) deficiency test is mandatory. Patients with G6PD deficiency (favism) can develop severe haemolytic anaemia from these drugs.

Management of Severe Malaria

Complicated or severe malaria is a medical emergency requiring immediate hospitalization. The treatment of choice is intravenous artesunate, which has been shown to reduce mortality more effectively than intravenous quinine. Once the patient can tolerate oral medication, a full course of ACT is completed.

Supportive Treatment and Complication Management

Patients with severe malaria require comprehensive supportive care:

• Intravenous fluid administration to manage dehydration and prevent circulatory collapse
• Blood transfusions for severe anaemia
• Anticonvulsants for seizures in cerebral malaria
• Continuous monitoring of respiratory and renal function
• Glucose supplementation to treat hypoglycaemia
• Respiratory support if pulmonary oedema or ARDS develops

Lifestyle and Recovery

During convalescence:

• Absolute rest is essential in the acute phase
• Adequate hydration supports recovery and renal function
• Nutritional support: A balanced diet helps the body rebuild haemoglobin levels and recover strength after the febrile illness
• Follow-up monitoring: Patients should be monitored in the weeks following treatment to detect recrudescence (parasites rebounding despite treatment)

Important: Having had malaria does not confer lasting immunity against reinfection. Preventive measures remain essential for every future visit to endemic regions.

---

Prevention, Prophylaxis, and Vaccine

Public health authorities combat malaria through vector control programs. These programs focus especially on insecticide spraying and larval habitat management. While these reduce the mosquito population, individual protection remains essential for travelers.

Personal Mosquito Bite Prevention

Since it is impossible to completely avoid mosquito bites in high-risk areas, minimizing the number of bites reduces infection risk. Recommended measures include:

• Bed nets (preferably insecticide-treated) around sleeping areas.
• Window and door screens.
• Insect repellents containing DEET (N,N-diethyl-meta-toluamide), picaridin, or IR3535 should be applied to exposed skin, particularly the face and hands.
• Permethrin-treated clothing: Applying permethrin to clothes adds a further layer of protection.
• Protective clothing: Wear long-sleeved shirts and long trousers, particularly from dusk to dawn, when Anopheles mosquitoes are most active.
• Avoid dark-colored clothing: Dark fabrics are more attractive to mosquitoes.
• Air conditioning: Keeping windows and doors closed while using AC reduces mosquito entry and discourages mosquito activity.

Prophylaxis

The cornerstone of malaria prevention for travelers is antimalarial drug prophylaxis: the regular administration of low-dose antimalarial medications before, during, and after travel to endemic areas. The active drug concentration in the blood prevents the parasite from establishing infection even if a bite from an infected mosquito occurs.

Key principles of malaria prophylaxis:

• Must begin before departure (timing depends on the chosen drug, ranging from 1 day to 1–2 weeks before travel).
• Must be continued throughout the stay in the endemic region.
• Must be continued after return (for 1–4 weeks depending on the drug, to cover parasites that may have entered the liver just before leaving the endemic area).

The choice of prophylactic drug depends on:

• The specific destination (and the local resistance profile of P. falciparum)
• Duration of travel
• Patient-specific factors (age, pregnancy, other medications, renal/hepatic function)

Commonly used prophylactic drugs include:

🩺 Always consult a travel medicine specialist or infectious disease physician at least 4–6 weeks before departure to receive a personalized prophylaxis recommendation based on your destination, health status, and travel duration. For more detail: Malaria Prophylaxis

Vaccine

The fight against malaria has reached a historic milestone with the development and WHO approval of the first malaria vaccines:

• RTS,S/AS01 (Mosquirix™): The first broadly approved malaria vaccine; reduces severe malaria by approximately 30% in young children in high-transmission settings
• R21/Matrix-M: A newer vaccine showing higher efficacy (approximately 75–80%) in Phase III trials; now recommended by WHO

Both vaccines are currently recommended by the World Health Organization for children living in areas with moderate to high malaria transmission (primarily sub-Saharan Africa). While they do not replace other preventive measures, they represent a landmark advance in reducing severe malaria cases and child mortality from the disease.

Research continues to develop next-generation vaccines with even higher efficacy and broader protection.

---

Frequently Asked Questions

How is malaria transmitted?

Malaria is transmitted primarily through the bite of an infected female Anopheles mosquito. Less common routes include blood transfusions, organ transplantation, sharing of contaminated needles, and vertical transmission from mother to child during pregnancy or childbirth.

What are the main symptoms of malaria, and when do they appear?

The main symptoms include high fever (the hallmark symptom), chills, profuse sweating, headache, muscle aches, nausea, vomiting, fatigue, and diarrhoea. Symptoms typically appear 7 to 30 days after an infected mosquito bite, depending on the Plasmodium species involved. Symptoms of P. vivax and P. ovale infections can appear months to years later due to dormant liver stages.

How is malaria treated?

Malaria is treated with antimalarial drugs, selected based on the infecting species, disease severity, and geographic origin (which determines likely drug resistance). When diagnosed and treated promptly, the prognosis is generally excellent. Severe malaria requires hospitalization and intravenous treatment. Never attempt self-treatment without medical supervision.

What preventive measures should I take when traveling to a malaria-endemic area?

Key prevention strategies include:

1. Antimalarial prophylaxis: Take the medication prescribed by your physician before, during, and after travel
2. Mosquito avoidance: Use insect repellents, insecticide-treated bed nets, protective clothing (long sleeves/trousers), and stay in air-conditioned or well-screened accommodation
3. Vaccination: Currently recommended for children residing in high-transmission areas; not yet widely available for travelers but evolving rapidly
4. Consult a travel medicine specialist at least 4–6 weeks before departure

---

Sources and Bibliography

• Centers for Disease Control and Prevention (CDC) – Malaria.
• World Health Organization (WHO) – Malaria Fact Sheet.
• Italian Ministry of Health – Malaria.
• White NJ, et al. Malaria. The Lancet. 2014;383(9918):723–735.
• WHO Guidelines for the Treatment of Malaria. 3rd edition. Geneva: World Health Organization; 2015.
• Olotu A, et al. Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. New England Journal of Medicine. 2013;368(12):1111–1120.
• Datoo MS, et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso. The Lancet. 2021;397(10287):1809–1818.